Tesamorelin
Tesamorelin
Tesamorelin is a stabilised GHRH analogue that stimulates the body's own pituitary to produce growth hormone in a natural pulsatile pattern. A Phase 3 human trial published in the New England Journal of Medicine demonstrated a 15.2% reduction in visceral adipose tissue over 26 weeks alongside improvements in triglycerides, waist circumference and quality of life. This clinical evidence base supported full FDA approval of tesamorelin (Egrifta) — making it the only GHRH analogue with a pharmaceutical approval for a metabolic indication.
Supplied as research-grade lyophilised peptide. Requires reconstitution with bacteriostatic water prior to use. For research purposes only.
Research Stack Builder
Build Your Research Stack
Curated combinations based on what researchers actually stack — backed by published data, priced to save.
Stack with Tesamorelin
Why researchers stack these
- 01GH axis + GLP-1 triple agonism stacked
- 02Collagen preserved during fat loss
- 03AMPK + insulin sensitivity as third layer
Full research context
Tesamorelin works directly on the pituitary via GHRH receptors — FDA-approved for visceral fat reduction. Most researchers add a GLP-1 agonist like Retatrutide to address the systemic metabolic component beyond the GH axis alone. GHK-Cu is the consistent third addition to support skin collagen during body recomposition. MOTS-c completes the metabolic picture through AMPK activation and improved peripheral insulin sensitivity.
Recovery & Repair Protocol
The most studied peptide combination for tissue repair, injury recovery & musculoskeletal healing
Why researchers stack these
- 01Non-competing structural repair pathways
- 02BPC-157 angiogenesis + TB-500 satellite cell activation
- 03GHK-Cu adds the extracellular matrix layer both lack
Full research context
BPC-157 and TB-500 are the two most frequently co-researched repair peptides in published literature, acting through complementary mechanisms — BPC-157 via nitric oxide pathways and angiogenesis, TB-500 via actin-sequestering and satellite cell activation. GHK-Cu rounds out the stack by supporting collagen synthesis and the extracellular matrix that both compounds do not directly address, while reducing the oxidative load that slows tissue recovery.
Metabolic & Body Recomposition
Most popular Peptide Pal stack — two non-competing fat loss axes with skin integrity support
Why researchers stack these
- 01GLP-1 triple agonism + GH axis — two distinct fat loss pathways
- 02Skin integrity preserved throughout recomposition
- 03Most purchased together on Peptide Pal
Full research context
Retatrutide and Tesamorelin address body composition through two non-competing mechanisms. Retatrutide's triple receptor agonism drives broad metabolic improvement and appetite regulation; Tesamorelin is FDA-approved for visceral adipose reduction through the growth hormone axis — a distinct mechanism. GHK-Cu supports skin integrity during recomposition; rapid fat loss without collagen support produces visible skin laxity that is far harder to address after the fact.
Cognitive Performance Stack
Neuropeptides studied for synergistic cognitive enhancement, focus & stress resilience — no sedation
Why researchers stack these
- 01BDNF stimulation balanced by GABA modulation
- 02Focus without anxiety — three non-competing pathways
- 03NAD+ fuels the neuronal energy demand
Full research context
Semax and Selank are registered pharmaceuticals with distinct mechanisms. Semax drives BDNF upregulation and cortical processing speed; Selank reduces the stress-induced cognitive interference that can blunt that effect, without sedation or dependency. NAD+ provides the cellular energy substrate that enhanced neuronal activity demands — researchers consistently report that this combination delivers balanced cognitive performance that neither compound achieves alone.
Skin & Glow Protocol
Collagen synthesis, antioxidant protection & melanin research in one comprehensive skin stack
Why researchers stack these
- 01Collagen, antioxidant & pigmentation — three skin pillars
- 02Tyrosinase inhibition counterbalances MC1R agonism for pathway research
- 03Structural integrity maintained alongside brightening
Full research context
GHK-Cu stimulates collagen synthesis and modulates over 4,000 genes involved in skin repair and inflammatory control — addressing the structural layer. Glutathione reduces oxidative stress and inhibits tyrosinase, producing measurable skin brightening with 30–35% tissue GSH increases confirmed in human RCTs. MT2 drives eumelanin synthesis via MC1R agonism, and researchers frequently combine it with Glutathione to study the interplay between melanocortin-driven pigmentation and tyrosinase inhibition simultaneously. Together these three represent the most comprehensive skin research protocol available.
Cellular Longevity Protocol
Three compounds that decline together with age — combined restoration for mitochondrial & cellular health
Why researchers stack these
- 01All three decline together with age — parallel restoration
- 02Mitochondrial energy, AMPK signalling & antioxidant protection
- 03Most complete cellular longevity protocol available
Full research context
NAD+, MOTS-c, and glutathione all decline measurably with age through parallel but distinct pathways. NAD+ restores sirtuin and PARP function essential for mitochondrial biogenesis and DNA repair — declining up to 50% by age 60. MOTS-c is the mitochondria-derived peptide that activates AMPK signalling and declines alongside NAD+; their combined restoration is the most researched longevity intervention. Glutathione provides the antioxidant protection that prevents cellular damage during the heightened metabolic activity that NAD+ and MOTS-c restoration drives — completing what researchers describe as the foundational cellular longevity triad.
Research & Studies
Peer-reviewed research supporting Tesamorelin
Tesamorelin: 15.2% Visceral Fat Reduction in Human Trial — Basis of FDA Approval
A landmark randomised, double-blind, placebo-controlled trial in 412 HIV-positive adults with excess abdominal fat demonstrated that tesamorelin produced a 15.2% reduction in visceral adipose tissue versus a 5.1% reduction in the placebo group at 26 weeks, a statistically and clinically significant difference of approximately 18cm² by CT imaging. Participants also showed significant improvements in triglyceride levels, waist circumference, and quality-of-life scores. The robust human evidence from this trial and subsequent studies supported FDA approval of tesamorelin (Egrifta) for excess abdominal fat in HIV-infected adults — making it the first GHRH analogue approved for a metabolic indication.
Tesamorelin Sustains Visceral Fat Reduction and Improves Metabolic Markers in Long-Term Human Study
A follow-up study evaluated the sustained effects of tesamorelin over 52 weeks in human participants, confirming that visceral fat reductions were maintained throughout the treatment period and that metabolic benefits — including improvements in triglycerides, IGF-1 normalisation, and waist circumference reduction — persisted with continued administration. Participants who discontinued tesamorelin after initial response showed reversal of visceral fat reductions within weeks, confirming that effects are treatment-dependent and establishing the mechanism as growth hormone axis stimulation rather than an irreversible metabolic reset. Quality-of-life improvements including reduced abdominal discomfort and improved body image were also sustained.